Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC
A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III randomized CABASTY trial. Rates of grade 3 or higher neutropenia or neutropenic complications were about 12 times lower with biweekly cabazitaxel 16 mg/m2 plus […]
Monoclonal Antibodies Linked to Reduced RSV Burden in Young Kids
Prophylactic use of three monoclonal antibodies was associated with substantial reductions in respiratory syncytial virus (RSV)-related infections and hospitalizations in children under 5, a systematic review and meta-analysis showed. Across 14 randomized controlled trials involving over 18,000 high-risk children, moderate- to high-certainty evidence showed that nirsevimab, palivizumab, and motavizumab were associated with significant reductions in […]
Anticoagulation Again Flops for Outpatient COVID-19
CHICAGO — For outpatient COVID-19, prophylactic anticoagulation with rivaroxaban (Xarelto) did not improve outcomes in elevated thrombotic risk patients, the PREVENT trial showed. Compared with placebo, giving the direct-acting oral anticoagulant (DOAC) for 35 days in non-hospitalized patients with symptomatic COVID-19 who had at least one risk factor for thrombosis didn’t reduce thromboembolic events or […]
Pathogens Head for Surgical Helmets During Orthopedic Surgeries
Bacterial colonization of surgical helmets, a prophylactic aspirin regimen for venous thromboembolism (VTE), and the value of virtual visits in pediatric orthopedics were examined in several studies at the American Academy of Orthopaedic Surgeons meeting. Pathogens and Surgical Helmets Nearly three-fourths of a sample of surgical helmets and surgeons’ foreheads swabbed after a day’s worth […]